Abstract
Psoriasis is a papulosquamous disease of multifactorial etiology. A combination of genetic and environmental agents is implicated in its pathogenesis. A variety of triggers, including infection, stress, and medications, have been recognized as precipitants of this disease. Nonsteroidal anti-inflammatory drugs, beta-blockers, lithium, synthetic antimalarials, and gold are the most common drugs implicated in precipitating psoriasis. We report a patient with psoriasis induced by initiation of losartan therapy, which resolved with discontinuation of the drug. The Naranjo adverse drug reaction probability scale score indicated that the association between losartan use and psoriasis was probable.
MeSH terms
-
Adrenergic beta-Antagonists / adverse effects
-
Adrenergic beta-Antagonists / pharmacology
-
Angiotensin II Type 1 Receptor Blockers / adverse effects*
-
Angiotensin II Type 1 Receptor Blockers / therapeutic use
-
Anti-Inflammatory Agents, Non-Steroidal / adverse effects
-
Anti-Inflammatory Agents, Non-Steroidal / pharmacology
-
Antimalarials / adverse effects
-
Antimalarials / pharmacology
-
Antimanic Agents / adverse effects
-
Antimanic Agents / pharmacology
-
Humans
-
Lithium / adverse effects
-
Losartan / adverse effects*
-
Losartan / therapeutic use
-
Male
-
Middle Aged
-
Psoriasis / chemically induced
-
Psoriasis / diagnosis*
-
Psoriasis / drug therapy
Substances
-
Adrenergic beta-Antagonists
-
Angiotensin II Type 1 Receptor Blockers
-
Anti-Inflammatory Agents, Non-Steroidal
-
Antimalarials
-
Antimanic Agents
-
Lithium
-
Losartan